Igenomix was created when it was spun out from Instituto Valenciano de Infertilidad (IVI) in 2011. Today it is one of the world’s leading providers of advanced services in reproductive genetics, operating from eight laboratories worldwide.
Its constant efforts in R&D enable Igenomix to create and develop specific tools to support professionals in the field of reproductive medicine. Specialist services offered include PGS (Pre-Implantation Genetic Screening), NACE (Non-invasive Prenatal Test); CGT (Carrier Genetic Test); PGD (Preimplantation Genetic Diagnosis) and ERA (Endometrial Receptivity Array).
In the media
1st April 2019
Evolving investments in gene technology
17th April 2019
Selection of New Probiotics for Endometrial Health
EC, SG, and DR are employed by Biopolis; IM, MG-M, and CS are employed by Igenomix; CS-D is employed by Ferring Pharmaceuticals. The remaining authors declare that the research was
16th April 2019
Synchrony Financial (SYF) Holder Norman Fields Gottscho Capital Management Trimmed Holding by $1.52 Million; Rampart Investment Management Company Increased Dominion Energy (D) Holding by $2.22 Million as Shares Rose
Some Historical SYF News: 12/03/2018 – Redefining Success in IVF: SYNCHRONY by Igenomix Brings in a New Era, a New Hope for Infertile Couples; 17/05/2018 – SYNCHRONY FINL BOOSTS QTR DIV